Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAPiS Study of iPS cell-derived cardiomyocyte spheroids in severe heart failure during CABG
jRCT2033210163Phase 2Active, not recruiting
- Sponsor
- Heartseed Inc.
- Start
- Jun 2021
- Countries
- 1
01
Overview
Phase 2, open-label trial in heart failure (HF) and coronary arteriosclerosis (2 arms), sponsored by Heartseed Inc. Primary endpoint: Safety. Started Jun 2021; status: active, not recruiting.
02
Conditions
heart failure (HF)coronary arteriosclerosis
Beyond the preview
Go deeper on jRCT2033210163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033210163.